What smart money is saying about Thermo Fisher Scientific Inc.
5 funds in our archive have pitched Thermo Fisher Scientific Inc. — most recently Baron Health Care Fund in December 2025.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Get an email when a fund writes about it
Position history
Between Q4 2024 and Q3 2026, 21 fund letters reported a position in Thermo Fisher Scientific Inc. — 9 opened or added to the position, 4 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 5 | 0 | 0 | 0 |
| Q2 2026 | 16 | 9 | 4 | 0 |
| Q4 2025 | 0 | 0 | 0 | 1 |
| Q3 2025 | 0 | 0 | 0 | 1 |
| Q2 2025 | 0 | 0 | 0 | 2 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Fund activity · 21 positions · 13 moves
- August 2026
Listed in Guinness Global Innovators Fund’s reported holdings.
Thermo Fisher Scientific Inc. - July 2026
“Danaher: A minor disappointment in Biotechnology but improving underlying markets Danaher also reported its second-quarter results during the month. The report beat market expectations on both revenue and earnings per share. The disappointment lay instead in the performance of the company's most important segment, Biotechnology, which came in below expectations, sending the Danaher share down by more than 15% during the day. The dominant explanation is that a couple of larger orders for major customers, scheduled for delivery in the second and third quarters, are instead being pushed into 2027 as a result of facility and scheduling issues at those customers. As a result, Danaher lowered its full-year guidance. Since the growth narrative sits within Biotechnology, which also carries higher profitability than the group as a whole, the impact is amplified. Underlying order intake for Biotechnology nevertheless remained strong, growing by around 15% for both equipment and key consumables. This is the second consecutive quarter of rapid order growth. The positive trend in Bioprocessing was also confirmed by Thermo Fisher, which said that the improved customer activity in biotech is now beginning to translate into actual revenue, and which raised its full-year guidance. A further data point supporting this thesis came recently from US-based Repligen, whose business consists 100% of Bioprocessing (equipment and consumables). As the fund has noted previously, the company often serves as a good indicator, since its order intake is a pure measure of Danaher's and Thermo Fisher's most important growth engine. During the second quarter, book-to-bill improved sharply sequentially and was said to be clearly above 1.0x, while the order book is being built up ahead of 2027. Order trends are strong overall, and China has improved markedly (+60% in the first half), accounting for 8–10% of Thermo's and Danaher's respective revenue. There is also growing discussion around reshoring production. Repligen has won several large capacity expansion projects and, according to the company, is “on track to win a third within the coming weeks”, which confirms that this investment cycle is also under way. The fund increased its holding in Danaher on the day of the report, as the share price decline was judged to be excessive. Danaher and Thermo Fisher account for 5.2% and 4% respectively of Kavaljer Investmentbolagsfond”
Thermo Fisher Scientific Inc. - July 2026
Listed in WS Lindsell Train North American Equity Fund’s reported holdings.
Thermo Fisher Scientific Inc. - July 2026
“Thermo Fisher (+12%) and Prada (+7%) both delivered pleasing results, largely outperforming their peers in the Life Sciences and Luxury sectors respectively.”
Thermo Fisher Scientific Inc. - July 2026
“Stock selection remained strong across several structural growth themes. Notable contributors included BayCurrent, Thermo Fisher, Expedia, Spotify and Full Truck Alliance.”
Thermo Fisher Scientific Inc. - June 2026
Listed in Harding Loevner Global Equity’s reported holdings.
Thermo Fisher Scientific Inc. - June 2026
“We added to the portfolio’s holdings in Intuit, Lowe’s, Medtronic, Meta (Facebook), Nike, PepsiCo, TE Connectivity, Thermo Fisher Scientific, and Tyson Foods.”
Thermo Fisher Scientific Inc. - June 2026
Listed in Artisan Partners Value Equity Strategy’s reported holdings.
Thermo Fisher Scientific Inc. - June 2026
Listed in Baron Health Care Fund’s reported holdings.
Thermo Fisher Scientific Inc. - New positionClearBridge Investments Value StrategyJune 2026
“In addition to the transactions discussed above, we initiated new positions in Vulcan Materials in the materials sector, TGS in the energy sector, FedEx Freight in the industrials sector, Brookfield Infrastructure in the utilities sector and Thermo Fisher Scientific in the health care sector.”
Thermo Fisher Scientific Inc. - June 2026
“Recent Activity During the second quarter, we initiated a new position in the aerospace and defense focused proprietary component manufacturer, Arxis . We took advantage of market volatility to add to our electrical systems and components designer and manufacturer, Amphenol , and also continued building our recently initiated position in the semiconductor equipment manufacturer, Lam Research. To finance these purchases, we exited two investments: Thermo Fisher Scientific , and Intuit , and reduced nine existing positions.”
Thermo Fisher Scientific Inc. - June 2026
“Recent Activity During the second quarter, we initiated a new position in the aerospace and defense focused proprietary component manufacturer, Arxis. We took advantage of market volatility to add to our electrical systems and components designer and manufacturer, Amphenol, and also continued building our recently initiated position in the semiconductor equipment manufacturer, Lam Research. To finance these purchases, we exited two investments: Thermo Fisher Scientific, and Intuit, and reduced nine existing positions.”
Thermo Fisher Scientific Inc. - AddedBCV Asset Management Antares Total Return StrategiesJune 2026
“We redeployed the proceeds into long-term compounders penalized by market anxiety—including adding to our existing positions of Amazon and Thermo Fisher Scientific.”
Thermo Fisher Scientific Inc. - New positionLiontrust Global Innovation FundJune 2026
Listed in Liontrust Global Innovation Fund’s reported holdings.
Thermo Fisher Scientific Inc. - June 2026
“We added materially to existing holdings on the same logic: Apple’s share count rose c.90% (now the Fund’s largest position at 5.4%), Danaher, Thermo Fisher, L’Oréal and Ferrari were all more than doubled, and Lilly, Amazon, Alphabet and Meta increased.”
Thermo Fisher Scientific Inc. - New positionLiontrust GF Global Innovation FundJune 2026
Listed in Liontrust GF Global Innovation Fund’s reported holdings.
Thermo Fisher Scientific Inc. - June 2026
“We added materially to existing holdings on the same logic: Apple’s share count rose c.90% (now the Fund’s largest position at 5.4%), Danaher, Thermo Fisher, L’Oréal and Ferrari were all more than doubled, and Lilly, Amazon, Alphabet and Meta increased.”
Thermo Fisher Scientific Inc. - June 2026
“Trading Activity 2Q During the quarter we added to the Fund’s positions in Danaher, Thermo Fisher Scientific, and Martin Marietta Materials at prices we think offer substantial upside with favorable risk profiles.”
Thermo Fisher Scientific Inc. - June 2026
“Portfolio activity beyond the entries and exits above was more muted and tilted toward trims. Beyond the exits of Accenture and Salesforce, we also trimmed our holdings of Alphabet, Amazon, Bio-Techne, SiriusXM and Thermo Fisher, partially offset by additions to Danaher and Global Payments.”
Thermo Fisher Scientific Inc. - June 2026
“Thermo Fisher Scientific (TMO), Moody’s (MCO), & Sherwin-Williams (SHW) We also exited our positions in Thermo Fisher Scientific, Moody’s, and Sherwin-Williams.”
Thermo Fisher Scientific Inc. - New positionKavaljer InvestmentbolagsfondMay 2026
“New positions are Alphabet and Thermo Fisher.”
Thermo Fisher Scientific Inc.
Also mentioned · 1
These funds discuss Thermo Fisher Scientific Inc. — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedGeneration IM Global Equity StrategyJuly 2026
“In our base case we model around 8% revenue and 16% unlevered earnings growth annually over the next five years. We are impressed with West’s management team, which receives a 2 on our rating of Management Quality. This August the company will appoint only its seventh chief executive in more than a century – testament to the long-term culture of the business. The incoming CEO, Michel Lagarde of Thermo Fisher Scientific, is a serious hire.”
Thermo Fisher Scientific Inc.
Fund coverage · 5 theses
- Baron Health Care FundDecember 2025
Thermo Fisher Scientific Inc. is a dominant life science tools company with improving end markets and a path to accelerating organic and earnings growth.
Read the full thesis - Baron Health Care FundSeptember 2025
Thermo Fisher Scientific Inc. is a competitively advantaged life sciences tools company poised for accelerated growth, expecting 3%-6% organic revenue growth in 2026-2027 and over 7% beyond, following a challenging period.
Read the full thesis - Artisan Value Equity StrategyJune 2025
Thermo Fisher Scientific (TMO) is a leading life science tools company with strong growth potential in fast-growing markets, solid financials, and a largely recurring revenue model, making it an attractive investment despite current market challenges.
Read the full thesis - Loomis Sayles Growth FundJune 2025
Thermo Fisher Scientific (TMO) is well-positioned for long-term growth in the life sciences tools industry, with a strong focus on biopharma, anticipated high-single-digit revenue growth, and undervalued share price offering a compelling investment opportunity despite current market pessimism.
Read the full thesis - Lindsell Train North American Equity FundDecember 2024
Thermo Fischer is a leading global life sciences tools and diagnostics company that benefits from industry growth and recurring revenues, making it an attractive investment opportunity despite recent flat share performance.
Read the full thesis
Read every full thesis on Thermo Fisher Scientific Inc.
Unlock all 5 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→